Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1961 3
1962 7
1963 7
1964 3
1965 1
1966 5
1967 2
1968 2
1969 7
1970 1
1971 6
1972 9
1973 15
1974 8
1975 1
1976 5
1977 8
1978 7
1979 12
1980 7
1981 12
1982 7
1983 8
1984 10
1985 14
1986 9
1987 13
1988 12
1989 16
1990 17
1991 23
1992 18
1993 28
1994 32
1995 39
1996 43
1997 38
1998 59
1999 69
2000 91
2001 90
2002 101
2003 147
2004 172
2005 190
2006 214
2007 263
2008 313
2009 396
2010 464
2011 503
2012 591
2013 623
2014 639
2015 651
2016 696
2017 624
2018 614
2019 650
2020 677
2021 676
2022 630
2023 581
2024 558
2025 550
2026 464

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,384 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.
Ahn HS, Ahn JC, Cho JM, Lim KH, Han SH, Cho YK, Kim KH, Hong SJ, Lee CJ, Na JO, Sung KC, Choi K, Kim SY, Kim DH, Lee HC, Ihm SH, Youn JC, Choi JY, Kim SH, Kim KI, Sung JH, Pyun WB, Kim WS, Cho JS, Lee Y, Her SH, Cho EJ, Lee EM, Lee HY, Yoon YW, Lee JH, Kim W, Rhee SJ, Shin J. Ahn HS, et al. Among authors: kim kh. J Clin Hypertens (Greenwich). 2026 May;28(5):e70279. doi: 10.1111/jch.70279. J Clin Hypertens (Greenwich). 2026. PMID: 42130156 Free PMC article. Clinical Trial.
Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b-BMI-1/VEGF-A axis in ovarian cancer.
Cho JG, Kim SW, Yun E, Yoon S, Choi J, Yeom D, Lee A, Lee D, Jeong SJ, Chang W, Hwang WY, Kim Y, Na K, Kim KH, Suh DS, Choi KU, Park JH, Kim KI, Yoo KH, Kwon BS, Kim J. Cho JG, et al. Among authors: kim kh. Exp Mol Med. 2025 Dec;57(12):2782-2797. doi: 10.1038/s12276-025-01582-2. Epub 2025 Dec 5. Exp Mol Med. 2025. PMID: 41345229 Free PMC article.
Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.
Ahn JC, Lee CW, Ahn JH, Lim KH, Sohn IS, Sung KC, Kim KH, Bae JH, Hong SP, Jang WY, Jo SH, Han SH, Kim JB, Lee CJ, Lee JH, Kim N, Cho EJ, Sung JH, Ahn HS, Kim SY, Shin J, Seo SM, Hong SJ, Kim W, Park CG. Ahn JC, et al. Among authors: kim kh. Hypertension. 2026 Apr;83(4):e25810. doi: 10.1161/HYPERTENSIONAHA.125.25810. Epub 2026 Feb 20. Hypertension. 2026. PMID: 41717679 Free PMC article. Clinical Trial.
Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma.
Park J, Qiu M, Cho EJ, Seo S, Moon JH, Kim M, Mun H, Yun H, Park H, Lim A, Kang Y, Oh JW, Youk H, Kim SH, Seo Y, Kwon SM, Sung KS, Oh HJ, Cho KR, Yoon K, Kim NS, Jang SJ, Kim KH, Yoon KJ. Park J, et al. Among authors: kim kh. Cell Rep Med. 2026 Jul 21;7(7):102850. doi: 10.1016/j.xcrm.2026.102850. Epub 2026 Jun 11. Cell Rep Med. 2026. PMID: 42276053 Free PMC article.
Comprehensive proteogenomic characterization reveals clinically relevant molecular subtypes associated with medulloblastoma progression.
Park SM, Kim KH, Yoon JH, D'Angelo F, Choi SA, Kim CI, Koo H, Park S, Kim H, Sundara Raj S, Kim SS, Park AK, Koh EJ, Kim SI, Shim YM, Kwang-Hoon L, Kim EE, Phi JH, Jo YS, Nam DH, Hwang D, Hyeon DY, Huh S, Kwon HJ, Ha S, Park S, Shin H, Kwon JT, Yoo H, Gwak HS, D Taylor M, Park BJ, Sa JK, Kim Y, Iavarone A, Park SH, Kim SK, Park JB. Park SM, et al. Among authors: kim kh. Exp Mol Med. 2026 Jun;58(6):1885-1899. doi: 10.1038/s12276-026-01732-0. Epub 2026 Jun 5. Exp Mol Med. 2026. PMID: 42249086 Free PMC article.
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.
Cohen IJ, Bochi-Layec AC, Lemoine J, Jenks S, Bayat P, Kim KH, Zhao H, Ugwuanyi O, Stella F, Ghilardi G, Gabrielli G, McCuaig S, Iatrou A, Vlachonikola E, Karipidou M, Bouziani E, Espie D, Ramasubramanian R, Agathangelidis A, Bhosale A, Paruzzo L, Medico G, Kolar B, Bugrovsky R, Guruprasad P, Wang LP, Harris J, Arons E, Zhang Y, Pajarillo R, Kreiger PA, Day CP, Sahinalp SC, Wu CH, Santi A, Fulmer B, Cases M, Palmer MB, Porazzi P, Wherry EJ, Kreitman RJ, Tiacci E, Apostolidis SA, Behrens EM, Bhoj V, Sanz I, Inghirami G, Schuster SJ, Ghia P, Stamatopoulos K, Ruella M. Cohen IJ, et al. Among authors: kim kh. Sci Transl Med. 2026 Feb 4;18(835):eadr9382. doi: 10.1126/scitranslmed.adr9382. Epub 2026 Feb 4. Sci Transl Med. 2026. PMID: 41637528
11,384 results
You have reached the last available page of results. Please see the User Guide for more information.